Loading...
XNAS
PTIX
Market cap343kUSD
Jul 09, Last price  
0.22USD
1D
15.79%
1Q
-62.39%
Jan 2017
-99.95%
Name

Protagenic Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:PTIX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-5.63%
Rev. gr., 5y
%
Revenues
0k
0018,721,00036,982,000113,884,00069,089,00040,026,00085,000000000000000
Net income
-5m
L-6.67%
-2,234,000-94,470677,000-4,149,000-115,766,000-29,470,000-19,727,000-1,027,000-1,079,000-476,000-2,276,000-2,260,000-2,558,000-1,751,000-2,548,735-4,523,000-3,556,000-5,000,000-5,525,000-5,156,250
CFO
-4m
L-1.81%
-842,000-44,000931,000-5,210,0004,355,000-3,015,000-11,250,000-324,000-790,000-378,000-1,140,319-1,380,089-1,071,188-487,990-1,348,779-2,798,614-1,993,814-3,703,776-4,216,517-4,140,350
Dividend
Dec 05, 20050.464 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Protagenic Therapeutics, Inc. is a biopharmaceutical company in its pre-clinical phase, dedicated to discovering and formulating treatments for neuropsychiatric and mood disorders that are related to stress. Its flagship compound, PT00114, is a laboratory-produced variant of teneurin carboxy-terminal associated peptide, a naturally occurring brain signaling peptide recognized for its capacity to moderate excessive stress reactions. The firm was established in 2016 and maintains its principal office in New York, New York.
URL
https://protagenic.com/
IPO date
Dec 18, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT